Table 4.

Summary of ALK-positive thyroid cancers from prior studies with basic clinicopathologic information

ALK “+” /total, n (%), histologic type	Female/ Male	Age, average (range), years	Morphologic variants and features	Recurrence?	Fusion partner	Reference
1¼98, 2.2%, PTC	11:0	38 (13–68)	Diffuse sclerosing, n=3; iFV, n=6^	No	EML4, n=8	Chou et al 2015
2/129,1.5%, FVPTC	n.a.	n.a.	PTC, n=2	No (n=1)	EML4, TFG	McFadden et al 2014
4/392, 1%, thyroid carcinomas	3:1	37 (13–50)	Classic, n=2; solid, n=1; FV (ETE), n=1;	No	STRN, n=2	Park et al 2015
10/116, 8.6%, PTC	8:2	42 (34–47)	iFV, n=4; classic, n=2; FV PTC, NOS, n=4	Yes, 1/8	EML4, n=6; STRN, n=4	Bastos et al 2018
1/15, PTC	0:1	31	Classic PTC, n=1	No	EML4	Cipriani et al 2017
1 PTC#	0:1	62	TCV PTC	Yes, DM	EML4	Demeure et al 2014
1/12, PTC*	0:1	27	Classic PTC	No	EML4	Pfeifer et al 2019
1/59, PTC^^	0:1	60	Classic PTC	AWD, 5 y	EML4	van der Tuin et al 2019
3/303, 1%, PTC	3:0	10 (7–15)	PTC, pN+, n=1; PTC, NOS, n=2	N.A.	EML4, STRN, GTF2IRD1	Vanden Borre et al 2017
3/75, thyroid carcinomas	1:0§	71	Classic PTC, n=2; ATC, n=1	AWD§	STRN	Perot et al 2014, Godbert et al 2015
3/84,3.5% PDTC; 0/33 ATC	1:2	(30–89)¶	PDTC, n=3	Died, n=2	STRN, EML4, CCDC149	Landa et al 2016
7/77 (9%), PTC~	5:2	23 (16–34)	FV PTC, n=1; PTC NOS, n=6	n.a.	EML4, n=2	Arndt et al 2018

^{^}There were also mixed PTC (n=2), tall cell variant of PTC (n=1), oncocytic PTC (n=1), Warthin-like PTC (n=1). Only EML4, as ALK fusion partner, was specifically tested for.

^#Stable disease after 6 months of Crizotinib treatment

^*Thyroid carcinomas negative for common mutations (e.g., BRAF, RAS)

^{^^}RAI-refractory thyroid carcinomas

^§The sex of two patients was not reported. Response after 6 months of Crizotinib therapy.

^¶Age of individual patients was not reported

^~PTC in radiation exposed patients